Advertisement

Topics

Hybrigenics Company Profile

21:38 EST 19th January 2019 | BioPortfolio

Hybrigenics is a pathway-based drug discovery company that identifies new drug targets and therapeutic molecules through a combination of high throughput protein interaction mapping, in-depth functional validation and leading-edge chemical screening technologies. Hybrigenics is the first spin-off of the Pasteur Institute which has supported and maintained tight links with the Company since its inception in 1998. Hybrigenics has raised 47 Million Euro from Venture capital funds to date and has acquired an extensive patent estate covering technologies, bioinformatics, targets as well as products.Hybrigenics has developed a strong international network of Academic collaborators, and has an on-going strategy to further develop collaborations with the pharmaceutical and biotechnology industry. The Company has demonstrated over the years its competitiveness and has expanded to international markets. Hybrigenics has its headquarters in central Paris and a subsidiary in the Netherlands after acquisition of Semaia BV. Semaia was co-founded by Professors Hans Bos and Hans Clevers and is specialized in the discovery and development of small molecules that regulate defective intracellular signal transduction in cancer and diabetes. Hybrigenics has also a representative office in Boston, USA.The Company has entered into strategic collaborations with leading Pharmaceutical Companies (Incyte, Merck, Lynx, OGS-UCB, Servier, XTL) and renowned Academic Institutes (Pasteur, Curie, INSERM, CNRS, Hubrecht, SIMM-Chinese Academy of Sciences) to contribute via its expertise and technology platforms to the drug discovery process.Hybrigenics currently runs internal drug discovery programs in oncology and collaborates with pharmaceutical companies both in oncology and other therapeutic areas for joint research. Hybrigenics gives also access to its functional Yeast-two-Hybrid platform as a fee- for-service activity.

Location

3-5 impasse Reille
Paris
75014
France

Contact

Phone: 33 1 5810 3800
Fax: 33 1 5810 3849
Email: careers@hybrigenics.com


News Articles [9 Associated News Articles listed on BioPortfolio]

Hybrigenics (ALHYG) - Termination of coverage

Edison Investment Research - Pharmaceuticals & healthcare - Hybrigenics: Edison Investment Research is terminating coverage on Hybrigenics (ALHYG). Please note you should no longer rely on any previou...

Update: French Biotech Considers Takeover After Failed Leukemia Drug Trial

Update (14/01/2019): An anonymous French company on Euronext has made an offer to take over Hybrigenics Pharma. This takeover bid could be good news for Hybrigenics, which has been planning to dissolv...

Almac Discovery Appoints Biology VP

Dr. Xavier Jacq has held positions at Sanofi-Synthelabo, Hybrigenics, Lectus Therapeutics, and AstraZeneca

Almac Discovery Names Biology VP

Dr. Xavier Jacq has held positions at Sanofi-Synthelabo, Hybrigenics, Lectus Therapeutics, and AstraZeneca

Hybrigenics SA ALHYG Financial and Strategic SWOT Analysis Review [Report Updated: 23052018] Prices from USD $125

Hybrigenics SA ALHYG Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalDa...

Failed Leukemia Drug Trial Spells Doom for French Biotech

The French biotech Hybrigenics Pharma is heading towards dissolution after its only treatment in development failed in a Phase II trial for acute myeloid leukemia. Although the trial in 110 patients w...

Hybrigenics SA ALHYG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06072018] Prices from USD $250

SummaryHybrigenics SA Hybrigenics is a biopharmaceutical company that develops new targets and therapies against proliferative and noncancerous diseases. Its lead product candidate Inecalcitol, is a v...

Hybrigenics SA ALHYG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryHybrigenics SA Hybrigenics is a biopharmaceutical company that develops new targets and therapies against proliferative and noncancerous diseases. Its lead product candidate Inecalcitol, is a v...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Hybrigenics

Hybrigenics is a pathway-based drug discovery company that identifies new drug targets and therapeutic molecules through a combination of high throughput protein interaction mapping, in-depth function...

More Information about "Hybrigenics" on BioPortfolio

We have published hundreds of Hybrigenics news stories on BioPortfolio along with dozens of Hybrigenics Clinical Trials and PubMed Articles about Hybrigenics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hybrigenics Companies in our database. You can also find out about relevant Hybrigenics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record